Faxeladol

Faxeladol

SCHEMBL465057

CN(C)C[C@@H]1CCCC[C@H]1c1cccc(O)c1.Cl

nearest known ligand 0.49

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

OPRM1SLC6A2SLC6A4

The experimentally established mechanism targets of Faxeladol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
SLC6A4 known ✓ P31645 9/20 0.49
SLC6A2 known ✓ P23975 6/20 0.49
OPRM1 known ✓ P35372 6/20 0.49
MEN1 O00255 1/20 0.49
OPRD1 P41143 1/20 0.49
OPRK1 P41145 1/20 0.49
KMT2A Q03164 1/20 0.49
HTR2A P28223 1/20 0.49
HTR2C P28335 1/20 0.49
HTR2B P41595 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Faxeladol SCHEMBL465056 1.00 SLC6A4 (0.49) SLC6A4SLC6A2OPRM1MEN1OPRD1
Faxeladol SCHEMBL7893759 1.00 SLC6A4 (0.49) SLC6A4SLC6A2OPRM1MEN1OPRD1
Faxeladol SCHEMBL7882332 1.00 SLC6A4 (0.49) SLC6A4SLC6A2OPRM1MEN1OPRD1
Faxeladol SCHEMBL5393347 0.99 SLC6A4 (0.48) SLC6A4SLC6A2OPRM1MEN1OPRD1
Faxeladol SCHEMBL3417844 0.99 SLC6A4 (0.48) SLC6A4SLC6A2OPRM1MEN1OPRD1
Faxeladol SCHEMBL149508 0.99 SLC6A4 (0.50) SLC6A4SLC6A2OPRM1MEN1OPRD1
Faxeladol SCHEMBL28793358 0.99 SLC6A4 (0.50) SLC6A4SLC6A2OPRM1MEN1OPRD1
Faxeladol SCHEMBL30616185 0.99 SLC6A4 (0.50) SLC6A4SLC6A2OPRM1MEN1OPRD1
Faxeladol SCHEMBL354208 0.99 SLC6A4 (0.50) SLC6A4SLC6A2OPRM1MEN1OPRD1
Faxeladol SCHEMBL5686250 0.99 SLC6A4 (0.50) SLC6A4SLC6A2OPRM1MEN1OPRD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3241550-B1 (1R, 2R)-3-(DIMENTHYL AMINO-1-ETHYL-2-METHYL-PROPYL) PHENOL FOR TREATING PAINFUL INFLAMMATIONS GRUENENTHAL GMBH (DE) 2020-07-22 EP disclosed
EP-3662904-A1 USE OF (1R, 2R)-3-(DIMENTHYL AMINO-1-ETHYL-2-METHYL-PROPYL) PHENOL FOR TREATING PAINFUL INFLAMMATIONS Grünenthal GmbH (DE) 2020-06-10 EP disclosed
EP-3241550-A1 (1R, 2R)-3-(DIMENTHYL AMINO-1-ETHYL-2-METHYL-PROPYL) PHENOL FOR TREATING PAINFUL INFLAMMATIONS Grünenthal GmbH (DE) 2017-11-08 EP disclosed
EP-1562567-B1 COMBINATION OF SELECTED ANALGESICS AND COX-II INHIBITORS GRUENENTHAL GMBH (DE) 2017-06-14 EP disclosed
US-20130245125-A1 HCl Polymorphs of 3-((2-(Dimethylamino)methyl(cyclohex-1-yl))phenol GRUENENTHAL GMBH (DE) 2013-09-19 US disclosed
US-8404749-B2 Method of inhibiting inflammatory pain GRUENENTHAL GMBH (DE) 2013-03-26 US disclosed
US-20120178809-A1 Salt of Dimethylaminomethyl-Phenyl-Cyclohexane and Crystalline Forms Thereof GRUENENTHAL GMBH (DE) 2012-07-12 US disclosed
EP-1839654-B9 Use of (1R, 2R)-3-(3-dimenthyl amino-1-ethyl-2-methyl-propyl) phenol for treating inflammatory pain GRUENENTHAL GMBH (DE) 2012-01-11 EP disclosed
US-8084497-B2 C-(2-phenyl-cyclohexyl)-methylamine compounds for therapy of fibromyalgia GRUENENTHAL GMBH (DE) 2011-12-27 US disclosed
US-8058476-B2 Crystalline salt of hydrogen chloride and 3-[2-(dimethylamino)methyl-(cyclohex-1-yl)]phenol; inhibiting pain GRUENENTHAL GMBH (DE) 2011-11-15 US disclosed
US-20070142681-A1 Process for chlorinating tertiary alcohols GRUENENTHAL GMBH (DE) 2007-06-21 US disclosed
US-20070032552-A1 Salt of dimethylaminomethyl-phenyl-cyclohexane and crystalline forms thereof GRUENENTHAL GMBH (DE) 2007-02-08 US disclosed
US-20070032551-A1 Salt of dimethylaminomethyl-phenyl-cyclohexane and crystalline forms thereof GRUENENTHAL GMBH (DE) 2007-02-08 US disclosed
US-20060258741-A1 C-(2-phenyl-cyclohexyl)-methylamine compounds for the treatment of anxiety disorders GRUENENTHAL GMBH 2006-11-16 US disclosed
EP-1685829-A1 Use of (1RS,3RS,6RS)-6-dimethylaminomethyl-1-(3-methoxy-phenyl)-cyclohexane-1,3-diol for treating inflammatory pain Grünenthal GmbH (DE) 2006-08-02 EP disclosed
EP-1562567-A1 COMBINATION OF SELECTED ANALGESICS AND COX-II INHIBITORS Grünenthal GmbH (DE) 2005-08-17 EP disclosed
US-20050119349-A1 Process for chlorinating tertiary alcohols GRUENENTHAL GMBH (DE) 2005-06-02 US disclosed
EP-1499582-A1 METHOD FOR CHLORINATING TERTIARY ALCOHOLS Grünenthal GmbH (DE) 2005-01-26 EP disclosed
WO-2004047823-A1 COMBINATION OF SELECTED ANALGESICS AND COX-II INHIBITORS Grünenthal GmbH (DE) 2004-06-10 WO disclosed
WO-2003091199-A1 METHOD FOR CHLORINATING TERTIARY ALCOHOLS Grünenthal GmbH (DE) 2003-11-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120178809-A1 Salt of Dimethylaminomethyl-Phenyl-Cyclohexane and Crystalline Forms Thereof REN, PKD1, ACMSD SLC6A4 1254/4885SLC6A2 782/4885OPRM1 19/4885
US-20060258741-A1 C-(2-phenyl-cyclohexyl)-methylamine compounds for the treatment of anxiety disorders PNMT, HTR2C, HTR2A SLC6A4 52/4885SLC6A2 42/4885OPRM1 65/4885
US-20050119349-A1 Process for chlorinating tertiary alcohols ADH1C, ADH5, ADH1A SLC6A4 2388/4885SLC6A2 3649/4885OPRM1 446/4885
US-20070142681-A1 Process for chlorinating tertiary alcohols ADH1C, ADH1A, ADH5 SLC6A4 2790/4885SLC6A2 3926/4885OPRM1 378/4885
US-20130245125-A1 HCl Polymorphs of 3-((2-(Dimethylamino)methyl(cyclohex-1-yl))phenol HCLS1, PEAK1, PAH SLC6A4 878/4885SLC6A2 659/4885OPRM1 16/4885
US-20070032552-A1 Salt of dimethylaminomethyl-phenyl-cyclohexane and crystalline forms thereof REN, PKD1, ACMSD SLC6A4 1254/4885SLC6A2 782/4885OPRM1 19/4885
US-20070032551-A1 Salt of dimethylaminomethyl-phenyl-cyclohexane and crystalline forms thereof PKD1, RCC1, ACMSD SLC6A4 1718/4885SLC6A2 1992/4885OPRM1 262/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.